IVA Inventiva S.A.
USHealthcareAs of 2026-07-10 16:00
Why IVA matters now
Inventiva S.A. (IVA) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.30 with -5.08% on the session and $223.5M in market capitalization; recent performance reads 1-month -27.29% and YTD -23.23%.
The latest financial table shown here is Q4 2025, with revenue of $28.8K, net income of $-176.9M, and EPS of $-0.28. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -24.8%.
The latest indexable market news headline is "Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $15.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-68.24
P/S
94.77
EV/EBITDA
-2.89
DCF Value
$-0.12
FCF Yield
-24.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
35.1%
Operating Margin
-3037.3%
Net Margin
-7899.6%
ROE
1870.4%
ROA
-141.9%
ROIC
-66.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $28.8K | $-176.9M | $-0.28 |
| FY 2025 | $4.5M | $-340.2M | $-1.82 |
| Q2 2025 | $4.5M | $-175.9M | $-1.62 |
| Q4 2024 | $6.5M | $-135.2M | $-2.60 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$16.50
Target (Median)
$15.00
Target Range
$12.00 - $24.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
FR
Exchange
—
Beta
0.88
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.